Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test… Read more
Veracyte Inc (VCYT) - Total Assets
Latest total assets as of September 2025: $1.37 Billion USD
Based on the latest financial reports, Veracyte Inc (VCYT) holds total assets worth $1.37 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Veracyte Inc - Total Assets Trend (2011–2024)
This chart illustrates how Veracyte Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Veracyte Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Veracyte Inc's total assets of $1.37 Billion consist of 28.6% current assets and 71.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.4% |
| Accounts Receivable | $46.52 Million | 3.6% |
| Inventory | $21.75 Million | 1.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $102.30 Million | 7.9% |
| Goodwill | $745.80 Million | 57.4% |
Asset Composition Trend (2011–2024)
This chart illustrates how Veracyte Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Veracyte Inc's current assets represent 28.6% of total assets in 2024, a decrease from 82.2% in 2011.
- Cash Position: Cash and equivalents constituted 18.4% of total assets in 2024, down from 72.4% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 64.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is goodwill at 57.4% of total assets.
Veracyte Inc Competitors by Total Assets
Key competitors of Veracyte Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Veracyte Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Veracyte Inc generates 0.34x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Veracyte Inc generates $ 1.86 in net profit.
Veracyte Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.23 | 5.08 | 22.39 |
| Quick Ratio | 5.94 | 4.79 | 22.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $377.07 Million | $ 286.54 Million | $ 358.90 Million |
Veracyte Inc - Advanced Valuation Insights
This section examines the relationship between Veracyte Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.25 |
| Latest Market Cap to Assets Ratio | 2.03 |
| Asset Growth Rate (YoY) | 16.6% |
| Total Assets | $1.30 Billion |
| Market Capitalization | $2.63 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Veracyte Inc's assets at a significant premium ( 2.03x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Veracyte Inc's assets grew by 16.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Veracyte Inc (2011–2024)
The table below shows the annual total assets of Veracyte Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.30 Billion | +16.60% |
| 2023-12-31 | $1.11 Billion | -3.59% |
| 2022-12-31 | $1.16 Billion | -2.64% |
| 2021-12-31 | $1.19 Billion | +159.83% |
| 2020-12-31 | $457.16 Million | +66.11% |
| 2019-12-31 | $275.21 Million | +128.13% |
| 2018-12-31 | $120.64 Million | +53.35% |
| 2017-12-31 | $78.67 Million | -22.14% |
| 2016-12-31 | $101.03 Million | +34.20% |
| 2015-12-31 | $75.28 Million | +16.11% |
| 2014-12-31 | $64.84 Million | -18.57% |
| 2013-12-31 | $79.63 Million | +317.63% |
| 2012-12-31 | $19.07 Million | +82.44% |
| 2011-12-31 | $10.45 Million | -- |